Introduction
Studies have shown that T cells require two activating signals to express full effector functions. 1 One signal is provided following interaction of the TCR with an appropriate antigenic peptide-MHC complex on antigenpresenting cells (APC) or potentially immunogenic tumor cells. The second signal is provided by costimulatory molecules on the surface of the APC through interaction with their counter-receptors or ligands on antigen-specific T cells. 2 Among the large number of costimulatory molecules, which includes ICAM-1, leukocyte functionassociated antigen 3 (LFA-3), heat stable antigens (HSA, CD24), and CD40L, B7 plays an important role in T cell triggering. [3] [4] [5] Most tumors, particularly those of nonhematopoietic origin, do not express costimulatory molecules and thus fail to activate fully tumor-specific T cells. 6 It is thought that naive T cells may be rendered hyporesponsive or anergic if TCR ligation occurs in the absence of costimulatory signals. 3 Although many B7-negative murine tumor cells can be rendered more immunogenic by transfer of B7 genes, [7] [8] [9] [10] [11] [12] several poorly immunogenic tumors have failed to elicit antitumor responses even after transfer of B7.1 and/or B7.2 genes, 12, 13 indicating that B7.1 alone is not sufficient to elicit efficient antitumor immunity. We reasoned that lack of immunogenicity of some B7 gene-modified tumor cells may be due in part to poor antigen presentation below a level critical for triggering T cell precursors. Tumor cells may accomplish this by down-regulating expression of MHC molecules, or down-regulating processing and presentation of tumor-associated peptide antigens, or both. 14, 15 It has been shown that many tumor cells express low levels of MHC class I molecules to avoid immune recognition 16, 17 and most tumor cells express no MHC class II antigens. Tumor cells, transfected with MHC class I genes, [18] [19] [20] class II genes 21, 22 or the ␥-IFN gene 23, 24 to increase MHC expression and TAA presentation, demonstrated lower tumorigenicity and higher immunogenicity.
In these studies we operate on the premise that tumor cells express tumor-specific or tumor-associated antigens and full activation of T cells requires the delivery of antigenic peptide-MHC complex and costimulatory signals. [25] [26] [27] [28] We have transduced a weakly immunogenic tumor cell line MCA106 fibrosarcoma with the gene for B7.1, to provide a costimulatory signal to T cells, and/or the gene for ␥-IFN, to up-regulate MHC expression and increase potential signaling between TCRs and class I and/or class II MHC-peptide complexes. These double transfectants were used as tumor vaccines to stimulate tumor-specific immunity in tumor-bearing animals.
Results
Generation of MCA cell lines expressing B7.1, ␥-IFN or both using a retroviral vector system MCA106 tumor cells were infected with retroviral vectors containing the B7.1 gene, or the ␥-IFN gene or both. Transfectants were selected in growth medium containing G418 and sorted by flow cytometry. (Figure 1 ). There is no detectable ␥-IFN release from MCA and MCA/B7.1, while both MCA/␥ and MCA/␥/B7.1 produced significant levels of ␥-IFN (Table 1) . These transfectants have been maintained in vitro for 7-8 months, demonstrating their stable expression of B7.1, MHC class I and II, and production of ␥-IFN. tumor cells per mouse, all mice challenged with MCA and MCA/V formed tumors, the growth of tumors in MCA/B7.1 and MCA/␥ groups was significantly arrested and 50-67% of mice in these two groups remained tumor free ( Figure 2 ). No tumor growth was observed in the MCA/␥/B7.1 group when challenged at dose of 1 × 10 6 tumor cells per mouse in a 2 month period of observation (Figure 2 ). When the tumor-free mice in these three groups were challenged with 1 × 10 6 MCA cells 2 months later, no mice developed tumors, suggesting that the transfectants are able to induce long-term antitumor immunity. Failure of the gene-modified tumor cells to grow in immunocompetent B6 mice is not due to The therapeutic efficacy of MCA/␥/B7.1 cotransductants inversely correlates with the tumor burden To investigate the therapeutic effect of MCA/␥/B7.1 on larger tumor burdens, mice were challenged subcutaneously with 2 × 10 5 MCA. Tumors in these untreated animals were nonpalpable 3 days after challenge; solid, palpable tumor masses of 4-6 mm in diameter were observed by day 10, and by day 17, tumors were 10-15 mm in diameter. These mice bearing different tumor burdens were then treated by i.p. injection with MCA/␥/B7.1 (1 × 10 6 per mouse) three times at 1 week intervals. As shown in Figure 5 , untreated mice developed progressively growing tumors. All animals treated with MCA/␥/B7.1 cells on day 3 demonstrated complete tumor regression ( Figure 5 ). Mice treated with MCA/␥/B7.1 on day 10 showed a significant delay in MCA growth and two of five mice showed complete tumor regression ( Figure 5 ). However, when mice were treated on day 17, although tumor growth was significantly suppressed, no tumor regression was observed ( Figure 5 ).
Survival studies were also performed by immunizing 3, 10 or 17 days after parental tumor cell challenge. All mice treated with irradiated MCA on day 3 were dead or moribund within 5 weeks after MCA tumor challenge ( Figure 6 ). Eighty-three per cent (five of six) and 34% (two of six) mice treated with MCA/␥/B7.1 on day 3 and day 10, respectively, showed complete tumor regression ( Figure 6 ). No significant therapeutic benefit was observed when treatment began 17 days after tumor challenge ( Figure 6 ).
Coexpression of B7.1 and ␥-IFN on the same tumor cells is required for optimal therapy
Because MCA/␥/B7.1 is more effective than MCA/␥ or MCA/B7.1 in tumor-bearing mice, it would be useful to know whether these two molecules must be expressed on the same tumor cells for effective therapy. B6 mice were inoculated subcutaneously with 2 × 10 5 MCA tumor cells and treated 3 days later with mixtures of MCA/␥ and MCA/B7 or MCA/␥/B7.1 tumor cells as indicated in Table 2 . As shown in Table 2 , treatment with mixtures of MCA/␥ and MCA/B7.1 tumor cells had limited therapeutic effect. In contrast, five of six mice treated with 1 × 10 6 MCA/␥/B7.1 and four of six mice treated with 
× 10
5 MCA/␥/B7.1 tumor cells rejected the tumor. Therefore, the therapeutic effect requires expression of both ␥-IFN and B7.1 genes on the same tumor cells.
Mice immunized with MCA modified to express B7.1, ␥-IFN or both genes mount a specific CTL response Naive mice were immunized with 1 × 10 6 MCA or MCA transductants twice at 7 day intervals. Seven to 10 days after the second immunization, splenocytes from mice immunized with single or double gene-transduced tumor cells were removed and nylon wool-enriched spleen T cells were stimulated in vitro for 5 days with irradiated parental MCA cells. The cultured cells were then tested for CTL activity against parental MCA in a standard 51 Cr release assay. As indicated in Figure 7a , spleen cells from mice immunized with MCA elicited no significant CTL activity, while those from mice immunized with MCA/B7.1 or MCA/␥ induced a moderate level of CTL activity. However, spleen cells from mice immunized with MCA/␥/B7.1 revealed a high level of CTL activity against parental tumor MCA. CTL generated by any of these transfectants showed a maximum of 11% specific cytotoxicity (E:T = 60:1) against Yac-1 cells and 1% specific cytotoxicity (E:T = 60:1) against B16 cells. When nylon wool-enriched spleen T cells from tumor-bearing mice treated with these gene-modified tumor cells were restimulated in vitro, significant cytolytic activity toward parental MCA cells was also observed (Figure 7b ).
Immunization of mice with MCA/␥/B7.1 increased the CTL precursor frequencies Naive B6 mice were immunized with irradiated MCA, MCA/B7.1, MCA/␥ or MCA/␥/B7.1. Spleen cells were prepared 2 weeks later for CTL precursor analysis. As shown in Table 3 (Figure 3) . However, when used as a therapeutic vaccine to treat mice bearing established solid tumors, these singly transduced tumor cells induced a limited therapeutic effect. In contrast, coexpression of B7.1 and ␥-IFN by MCA106 tumor cells abolished their tumorigenicity and increased the immunogenicity so that they not only induced potent and complete protection against challenge with parental MCA106 but evoked a potent therapeutic effect. The results indicate that even poorly immunogenic tumors can be rendered highly immunogenic by providing them with not just the ability to costimulate but with increased expression of both MHC class I and class II gene products to amplify their potential to process and present potential tumor-associated antigens.
In this tumor model, failure of treatment using MCA/B7.1 or MCA/␥ to eliminate established solid tumors is not due to the inability of the singly modified tumor cells to induce antitumor responses since significant levels of CTL activity are induced in vitro in spleen cells from MCA/B7.1-or MCA/␥-treated tumor-bearing mice (Figure 7b ). Rather, failure may be due to the limited magnitude of the immune response which the singly modified tumor cells can elicit. In all cases, CTL activity in spleen cells primed with doubly modified tumor cells exceeds that in spleen cells from animals treated with either of the singly modified tumor cells. Furthermore, while data in Table 3 demonstrate that treatment with either B7 or ␥IFN gene-modified tumor cells may increase the number of measurable precursor CTLs specific for MCA106, treatment with the doubly modified tumor cells increases the number of precursors in a more than additive manner, indicating a synergistic interaction between the two modifications. Thus, the increased therapeutic effect by B7.1/␥-IFN gene-modified tumor cells may be in part a result of substantial quantitative differences in the CD8 + T cell-mediated immune response following treatment. Alternatively and/or concurrently, a larger array of tumor-specific precursor CTLs with TCRs which display a broader range of specificities for MCA106 TAA may be activated when T cells encounter higher levels of both class I-and class II-presented tumor antigens simultaneously with B7.1 exposure.
The experiments described here using mixtures of (Table 2) indicate that the optimal therapeutic effect requires increased MHC and B7.1 to be expressed on the same cells. Based on the widely accepted premise that two signals are required for T cell activation, tumor cells which are doubly transfected with B7.1 to costimulate T lymphocytes and ␥-IFN to increase antigen-specific signaling to both MHC class I-and MHC class II-restricted T cells may optimize the likelihood of concurrent ligation of CD28 and T cell receptors. Conceivably, when singly modified tumor cells are used for immunization, interaction by responsive T cells with one tumor cell expressing only B7 may sterically inhibit concurrent interaction with a second or third tumor cell expressing increased levels of MHC-antigen complexes. Thus, steric limitations on timing and delivery of the antigen-specific and costimulatory signals may be crucial for 31 who demonstrated that maximal CD4 + T cell activation 30 and efficient antitumor effect 31 occurred when the antigen-specific signal (transfected class II) and costimulation signal were delivered by the same cells.
In recently published work, Schoenberger et al 32 used a human peptide DNA construct as a model for a class I-presented tumor antigen in cells which were further modified to express the B7 costimulatory molecule. It was necessary to treat these TAA-expressing, B7-modified APC with ␥-IFN to increase class I before the engineered cells were significantly immunogenic. If, in fact it is the increased MHC expression elicited by the ␥-IFN treatment which modifies the immunogenicity, results of our in vivo mixing experiments suggest that ␥-IFN secreted by the singly ␥-IFN-transduced MCA is insufficient to elicit adequate or timely increases in MHC-peptide expression by adjacent B7-modified tumor cells and thereby increase their immunogenicity.
Depletion studies showed that antitumor immunity induced by MCA/B7.1 was primarily mediated by CD8 + cells, and to some extent by NK cells with little decrease in immunity following depletion of CD4 + cells. It would appear therefore that the response induced by B7 genemodified tumor vaccine was independent of CD4 + T cells. These results fit well with the notion that B7.1 + tumor cells primarily activate CD8 + T cells. 7, 9, 33 The results are also consistent with the previous observation that B7-CD28 interaction mediates NK cell activation. 34 The results of T cell subset depletion in studies using doubly transduced tumor cells indicate that the potent MCA/B7.1/␥-induced immunity has the additional requirement for CD4 T cells. The ␥-IFN-and B7-cotransduced tumor cells not only express increased levels of MHC class I but are also highly positive for MHC class II. The potential of these cells to express tumor antigens in the context of not only class I but class II as well to elicit CD4 T cell help may explain the increased efficacy of the doubly transduced vaccine and the loss of much of the added effect following depletion of class II-restricted, CD4 + T cells. The results also support and extend the previous observations that MHC class I and II gene-modified tumor vaccines are superior to single MHC class I or class II gene-modified tumor vaccines in eliciting antitumor immunity. 35 Our data suggest that B7-and ␥-IFN-cotransduced tumor cells, which are B7.1 + /MHC class I + and II
+
, may directly present TAA in the context of class I to CD8 + T cells and in the context of class II to CD4 + T cells. This notion is supported by our previous studies with B7 gene-modified human melanoma 36 and by the results of other investigators. [37] [38] [39] [40] We and other investigators demonstrated that purified CD8 + T cells were activated directly by B7 gene-modified syngeneic tumor cells in in vitro mouse studies 33, 37 or by B7 gene-modified autologous 36 or allogeneic 36, 38 
/II
− tumor cells directly present antigen to T cells. Also using bone marrow chimeric mice, Ostrand-Rosenberg and colleagues 40 showed that MHC class II gene-modified tumor vaccines directly present antigen to tumor-specific CD4 + T cells. Two other recent studies 32, 41 have also demonstrated the ability of B7-modified non-professional APC to directly present TAA and elicit class I-restricted CTL responses. Neither of these studies, nor do we here, dismiss the notion that B7 modification may also promote more classical APC pathways.
That alternative explanation as suggested by Huang et al 42 cannot be excluded. Through cross-priming experiments in bone marrow chimeras, these investigators showed that T cell priming by MHC class I + tumor cells is predominantly, although not exclusively, through the uptake and presentation of tumor antigens by the host APCs. Based on these experiments, we reason that except for the direct antigen presentation, immunization using tumor cells cotransfected with B7.1 gene plus ␥-IFN gene may activate NK cells through the costimulation by the interaction between B7 and CD28 34 and/or activate macrophages by ␥-IFN released by tumor vaccines. Activated NK cells and macrophages could play an important role in the destruction of tumor cells, facilitating the release of tumor antigens, and thus their uptake and presentation by host professional APCs, which in turn provide the optimal activation signals necessary to induce antitumor T cells, as demonstrated by Huang et al. 42 Thus, the co-expression of B7.1 and ␥-IFN on tumor cells may facilitate both direct and indirect presentation of tumor-associated antigens to the reactive T cells, including both CD4 + and CD8 + T lymphocytes. Although further experiments will be required to dissect the precise mechanisms of the cooperation of B7.1 and ␥-IFN or class I and class II in eliciting immunity, our results clearly show that tumor cells cotransduced with B7.1 and ␥-IFN are highly efficient tumor immunogens. Recently reported work by Yang et al 36 has demonstrated the increased ability of human melanomas to elicit potent tumor-specific CTL in vitro following transfection of these inherently immunogenic tumor cells with the gene for B7.1. If it is confirmed that other non-immunogenic or poorly immunogenic murine or human tumor cells can also be rendered more immunogenic by cotransfection with B7.1 and ␥-IFN, the method described in this study may have significant potential in developing immunotherapeutic strategies for treatment of human malignancies.
Materials and methods
Construction of a retroviral vector containing hB7.1 gene and tumor cell infection The retroviral vector, pLXSN/B7.1, containing full-length human B7.1 cDNA (a gift from Dr Freeman, Dana-Farber Cancer Institute, Boston, MA, USA 43 ) was constructed and introduced into packaging cell line PA317 as described elsewhere. 36 MCA/␥ was generated by transfection of MCA106 tumor cells with the gene for ␥-IFN retrovirus vector produced by DA packaging cells. 4 -irradiated (50 Gy) normal B6 splenocytes as feeder cells in RPMI 1640 medium containing 10% FBS as described by Widmer et al. 45 Twenty-four replicate wells were prepared for each responding cell number. Cultures were incubated in complete RPMI 1640 medium containing 2-mercaptoethanol (2-ME, 2 × 10 −5 m) at 37°C in 5% CO 2 for 8-10 days, and were then tested for lytic activity against MCA and P815 tumor cells using 51 Cr assay.
Calculation of CTL precursor frequencies
Estimates of CTL precursor (CTL-p) frequencies were obtained by fitting a straight line (via minimum 2 ) describing the relationship between cell number and the logarithm of the percentage of nonlytic (negative) wells, as described by Taswell. 46 Cultures were defined as positive when 51 Cr release values exceeded by at least 3 s.d. the mean values of control cultures containing normal spleen cells at limiting dilution, stimulating tumor cells and feeder cells.
Induction of CTL
Splenocytes (2-5 × 10 6 per well) from tumor immunized mice were cultured with irradiated (100 Gy) MCA cells at a lymphocyte to tumor ratio of 20:1 in 2 ml of RPMI 1640 medium containing 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 50 g/ml gentamicin, and 5 × 10 −5 m 2-ME in 24-well tissue culture plates (Costar, Cambridge, MA, USA). The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO 2 and fed on day 3 by removing medium and replenishing it with an equal volume of fresh medium. The cells were harvested on day 5 for CTL assay.
Cytotoxicity assay Target cells were labeled by incubation with 100 Ci of sodium 51 chromate for 1 hour at 37°C. They were washed three times in HBSS and resuspended in RPMI 1640 medium containing 10% FBS. Labeled target cells (0.1 ml at 5 × 10 4 cells/ml) were mixed with effector cells to yield several effector to target (E:T) ratios in 96 U-bottom plates and incubated at 37°C for 4 h. The supernatants were harvested and counted in a gamma spectrometer. The cytotoxic activity was calculated as follows: 
Statistical analysis
Life table analysis was used to test for differences between treatment groups within each experiment.
